0001522767 false Accelerated Filer --12-31 Q2 2020 0 0 350000 930000 0001522767 2020-01-01 2020-06-30 0001522767 2020-08-10 0001522767 2020-06-30 0001522767 2019-12-31 0001522767 MRMD:SeriesBConvertiblePreferredStockMember 2020-06-30 0001522767 MRMD:SeriesBConvertiblePreferredStockMember 2019-12-31 0001522767 MRMD:SeriesBConvertiblePreferredStockMember 2020-06-30 0001522767 MRMD:SeriesBConvertiblePreferredStockMember 2019-12-31 0001522767 MRMD:SeriesAConvertiblePreferredStockMember 2020-06-30 0001522767 MRMD:SeriesAConvertiblePreferredStockMember 2019-12-31 0001522767 MRMD:SeriesAConvertiblePreferredStockMember 2020-06-30 0001522767 MRMD:SeriesAConvertiblePreferredStockMember 2019-12-31 0001522767 2020-04-01 2020-06-30 0001522767 2019-04-01 2019-06-30 0001522767 2019-01-01 2019-06-30 0001522767 us-gaap:CommonStockMember 2018-12-31 0001522767 MRMD:CommonStockSubscribedButNotIssuedMember 2018-12-31 0001522767 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001522767 us-gaap:RetainedEarningsMember 2018-12-31 0001522767 us-gaap:NoncontrollingInterestMember 2018-12-31 0001522767 2018-12-31 0001522767 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001522767 MRMD:CommonStockSubscribedButNotIssuedMember 2019-01-01 2019-06-30 0001522767 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0001522767 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0001522767 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-06-30 0001522767 us-gaap:CommonStockMember 2019-06-30 0001522767 MRMD:CommonStockSubscribedButNotIssuedMember 2019-06-30 0001522767 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001522767 us-gaap:RetainedEarningsMember 2019-06-30 0001522767 us-gaap:NoncontrollingInterestMember 2019-06-30 0001522767 2019-06-30 0001522767 us-gaap:CommonStockMember 2019-12-31 0001522767 MRMD:CommonStockSubscribedButNotIssuedMember 2019-12-31 0001522767 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001522767 us-gaap:RetainedEarningsMember 2019-12-31 0001522767 us-gaap:NoncontrollingInterestMember 2019-12-31 0001522767 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001522767 MRMD:CommonStockSubscribedButNotIssuedMember 2020-01-01 2020-06-30 0001522767 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001522767 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001522767 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-06-30 0001522767 us-gaap:CommonStockMember 2020-06-30 0001522767 MRMD:CommonStockSubscribedButNotIssuedMember 2020-06-30 0001522767 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001522767 us-gaap:RetainedEarningsMember 2020-06-30 0001522767 us-gaap:NoncontrollingInterestMember 2020-06-30 0001522767 2020-03-31 0001522767 MRMD:CannabisMember 2020-01-01 2020-06-30 0001522767 MRMD:CannabisMember country:DE 2020-01-01 2020-06-30 0001522767 MRMD:CannabisMember country:IL 2020-01-01 2020-06-30 0001522767 MRMD:CannabisMember country:MD 2020-01-01 2020-06-30 0001522767 MRMD:CannabisMember country:MA 2020-01-01 2020-06-30 0001522767 MRMD:MassachusettsRealEstateMember us-gaap:SubsequentEventMember 2020-07-02 0001522767 MRMD:MassachusettsRealEstateMember us-gaap:SubsequentEventMember 2020-07-01 2020-07-02 0001522767 us-gaap:SubsequentEventMember MRMD:MassachusettsRealEstateMember 2020-07-01 2020-07-31 0001522767 MRMD:KPGOfAnnaLLCMember 2020-01-01 2020-06-30 0001522767 MRMD:MariMedAdvisorsIncMember 2020-06-30 0001522767 MRMD:MiaDevelopmentLLCMember 2020-06-30 0001522767 MRMD:MariHoldingsILLLCMember 2020-06-30 0001522767 MRMD:MariHoldingsMDLLCMember 2020-06-30 0001522767 MRMD:MariHoldingsNVLLCMember 2020-06-30 0001522767 MRMD:HartwellRealtyHoldingsLLCMember 2020-06-30 0001522767 MRMD:IRollieLLCMember 2020-06-30 0001522767 MRMD:ARLHealthcareIncMember 2020-06-30 0001522767 MRMD:KPGOfAnnaLLCMember 2020-06-30 0001522767 MRMD:KPGofHarrisburgLLCMember 2020-06-30 0001522767 MRMD:MariMedHempIncMember 2020-06-30 0001522767 MRMD:MeditaurusLLCMember 2020-06-30 0001522767 us-gaap:BuildingAndBuildingImprovementsMember srt:MinimumMember 2020-01-01 2020-06-30 0001522767 us-gaap:BuildingAndBuildingImprovementsMember srt:MaximumMember 2020-01-01 2020-06-30 0001522767 MRMD:TenantImprovementsMember 2020-01-01 2020-06-30 0001522767 us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-06-30 0001522767 us-gaap:MachineryAndEquipmentMember srt:MinimumMember 2020-01-01 2020-06-30 0001522767 us-gaap:MachineryAndEquipmentMember srt:MaximumMember 2020-01-01 2020-06-30 0001522767 us-gaap:MeasurementInputExpectedTermMember 2020-01-01 2020-06-30 0001522767 us-gaap:MeasurementInputExpectedTermMember 2019-01-01 2019-06-30 0001522767 srt:MinimumMember 2020-06-30 0001522767 srt:MaximumMember 2020-06-30 0001522767 srt:MinimumMember 2019-06-30 0001522767 srt:MaximumMember 2019-06-30 0001522767 MRMD:OptionsAndWarrantsMember 2020-01-01 2020-06-30 0001522767 MRMD:OptionsAndWarrantsMember 2019-01-01 2019-06-30 0001522767 MRMD:ConvertibleDebenturesPayableMember 2020-01-01 2020-06-30 0001522767 MRMD:ConvertibleDebenturesPayableMember 2019-01-01 2019-06-30 0001522767 MRMD:SeriesBConvertiblePreferredStockMember 2020-01-01 2020-06-30 0001522767 MRMD:ConvertiblePromissoryNotesMember 2020-01-01 2020-06-30 0001522767 MRMD:ConvertiblePromissoryNotesMember 2019-01-01 2019-06-30 0001522767 MRMD:KPGofAnnaLLCandKPGofHarrisburgLLCMember 2018-10-02 0001522767 MRMD:MariHoldingsILLLCMember 2018-10-02 0001522767 MRMD:KPGofAnnaLLCandKPGofHarrisburgLLCMember 2019-09-28 2019-10-02 0001522767 MRMD:KPGofAnnaLLCandKPGofHarrisburgLLCMember 2020-06-30 0001522767 MRMD:TheHarvestFoundationLLCMember 2019-08-31 0001522767 MRMD:TwoOwnersMember MRMD:TheHarvestFoundationLLCMember 2018-01-01 2018-12-31 0001522767 MRMD:TwoOwnersMember MRMD:TheHarvestFoundationLLCMember 2018-12-31 0001522767 MRMD:KindTherapeuticsUSAIncMember 2018-12-01 2018-12-31 0001522767 MRMD:KindTherapeuticsUSALLCMember 2018-12-31 0001522767 MRMD:KindTherapeuticsUSALLCMember MRMD:AnneArundelCountyMDMember 2019-10-31 0001522767 MRMD:PurchaseAgreementMember MRMD:MeditaurusLLCMember 2019-06-30 0001522767 MRMD:PurchaseAgreementMember MRMD:MeditaurusLLCMember 2019-06-01 2019-06-02 0001522767 MRMD:PurchaseAgreementMember MRMD:MeditaurusLLCMember 2019-05-31 0001522767 MRMD:MeditaurusLLCMember 2020-06-30 0001522767 MRMD:MeditaurusLLCMember 2019-05-31 0001522767 MRMD:AgriMedIndustriesOfPALLCMember MRMD:PurchaseAgreementMember 2018-07-31 0001522767 MRMD:AgriMedIndustriesOfPALLCMember MRMD:PurchaseAgreementMember 2018-07-01 2018-07-31 0001522767 MRMD:AgriMedIndustriesOfPALLCMember MRMD:PurchaseAgreementMember 2019-05-01 2019-05-31 0001522767 MRMD:TerraceIncMember 2020-06-30 0001522767 MRMD:TerraceIncMember 2019-12-31 0001522767 MRMD:MembersRSVPLLCMember 2020-06-30 0001522767 MRMD:MembersRSVPLLCMember 2019-12-31 0001522767 MRMD:ChoozeCorpMember 2020-06-30 0001522767 MRMD:ChoozeCorpMember 2019-12-31 0001522767 MRMD:GenCannaGlobalIncMember 2020-06-30 0001522767 MRMD:GenCannaGlobalIncMember 2019-12-31 0001522767 MRMD:IconicVenturesIncMember 2020-06-30 0001522767 MRMD:IconicVenturesIncMember 2019-12-31 0001522767 MRMD:TerraceIncMember 2019-05-01 2019-05-31 0001522767 MRMD:TerraceIncMember 2019-05-31 0001522767 MRMD:TerraceIncMember 2020-06-30 0001522767 MRMD:TerraceIncMember 2020-01-01 2020-06-30 0001522767 MRMD:MembersRSVPLLCMember 2018-08-31 0001522767 MRMD:MembersRSVPLLCMember 2018-08-01 2018-08-31 0001522767 MRMD:MembersRSVPLLCMember 2019-06-30 0001522767 MRMD:MembersRSVPLLCMember 2020-01-01 2020-06-30 0001522767 MRMD:ChoozeCorpMember 2019-01-31 0001522767 MRMD:MembersRSVPLLCMember 2018-12-31 0001522767 MRMD:GenCannaGlobalIncMember 2019-02-01 2019-02-28 0001522767 MRMD:GenCannaGlobalIncMember 2019-02-28 0001522767 MRMD:GenCannaGlobalIncMember 2019-12-01 2019-12-31 0001522767 MRMD:GenCannaGlobalIncMember 2019-12-31 0001522767 MRMD:GenCannaGlobalIncMember 2020-05-18 2020-05-19 0001522767 MRMD:GenCannaGlobalIncMember 2020-05-19 0001522767 MRMD:GenCannaGlobalIncMember MRMD:HempSeedsMember 2020-05-18 2020-05-19 0001522767 MRMD:IconicVenturesIncMember 2018-12-01 2018-12-31 0001522767 MRMD:IconicVenturesIncMember srt:MaximumMember 2018-12-31 0001522767 MRMD:BinskeMember MRMD:LicensingAgreementMember srt:MinimumMember 2019-07-01 2019-07-31 0001522767 MRMD:BinskeMember MRMD:LicensingAgreementMember srt:MaximumMember 2019-07-01 2019-07-31 0001522767 country:DE 2016-09-30 0001522767 country:DE 2020-06-30 0001522767 country:DE 2020-01-01 2020-06-30 0001522767 country:MD 2020-06-30 0001522767 country:MD 2020-01-01 2020-06-30 0001522767 country:MA MRMD:NonCannabisMember 2020-06-30 0001522767 country:MA MRMD:NonCannabisMember 2020-01-01 2020-06-30 0001522767 country:IL 2020-06-30 0001522767 country:IL 2020-01-01 2020-06-30 0001522767 country:DE MRMD:RetailSpaceMember 2020-06-30 0001522767 country:DE MRMD:RetailSpaceMember 2020-01-01 2020-06-30 0001522767 2019-01-01 2019-12-02 0001522767 2019-01-01 2019-12-31 0001522767 MRMD:LeasesAndSubleasesMember 2020-06-30 0001522767 MRMD:FirstStateCompassionCenterMember 2020-06-30 0001522767 MRMD:FirstStateCompassionCenterMember 2019-12-31 0001522767 MRMD:HealerLLCMember 2020-06-30 0001522767 MRMD:HealerLLCMember 2019-12-31 0001522767 MRMD:HighFidelityIncMember 2020-06-30 0001522767 MRMD:HighFidelityIncMember 2019-12-31 0001522767 MRMD:MarylandHealthAndWellnessCenterIncMember 2020-06-30 0001522767 MRMD:MarylandHealthAndWellnessCenterIncMember 2019-12-31 0001522767 MRMD:AtaloHoldingsIncMember 2020-06-30 0001522767 MRMD:AtaloHoldingsIncMember 2019-12-31 0001522767 MRMD:DelawareCannabisLicenseeMember 2015-10-01 2016-04-30 0001522767 MRMD:DelawareCannabisLicenseeMember 2016-05-01 2016-05-31 0001522767 MRMD:DelawareCannabisLicenseeMember 2016-05-31 0001522767 MRMD:DelawareCannabisLicenseeMember 2020-06-30 0001522767 MRMD:DelawareCannabisLicenseeMember 2019-12-31 0001522767 MRMD:HealerLLCMember MRMD:DrDustinSulakMember 2018-08-01 2019-06-30 0001522767 MRMD:HealerLLCMember MRMD:DrDustinSulakMember 2019-06-30 0001522767 MRMD:HighFidelityIncMember 2019-08-31 0001522767 MRMD:HighFidelityIncMember 2019-08-01 2019-08-31 0001522767 MRMD:MarylandHealthAndWellnessCenterIncMember MRMD:ConstructionLoanMember 2019-01-31 0001522767 MRMD:AtaloHoldingsIncMember 2019-07-31 0001522767 MRMD:AtaloHoldingsIncMember 2019-05-01 2019-07-31 0001522767 MRMD:CBDIsolateAndHempExtractMember 2020-06-30 0001522767 MRMD:CBDIsolateAndHempExtractMember 2019-12-31 0001522767 us-gaap:LandMember 2020-06-30 0001522767 us-gaap:LandMember 2019-12-31 0001522767 MRMD:BuildingsandBuildingImprovementsMember 2020-06-30 0001522767 MRMD:BuildingsandBuildingImprovementsMember 2019-12-31 0001522767 MRMD:TenantImprovementsMember 2020-06-30 0001522767 MRMD:TenantImprovementsMember 2019-12-31 0001522767 us-gaap:FurnitureAndFixturesMember 2020-06-30 0001522767 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001522767 us-gaap:MachineryAndEquipmentMember 2020-06-30 0001522767 us-gaap:MachineryAndEquipmentMember 2019-12-31 0001522767 us-gaap:ConstructionInProgressMember 2020-06-30 0001522767 us-gaap:ConstructionInProgressMember 2019-12-31 0001522767 MRMD:MortgageMember MRMD:BankOfNewEnglandMassachusettsPropertyMember 2020-06-30 0001522767 MRMD:MortgageMember MRMD:BankOfNewEnglandMassachusettsPropertyMember 2019-12-31 0001522767 MRMD:MortgageMember MRMD:BankOfNewEnglandDelawarePropertyMember 2020-06-30 0001522767 MRMD:MortgageMember MRMD:BankOfNewEnglandDelawarePropertyMember 2019-12-31 0001522767 MRMD:MortgageMember MRMD:DuQuoinStateBankIllinoisPropertiesMember 2020-06-30 0001522767 MRMD:MortgageMember MRMD:DuQuoinStateBankIllinoisPropertiesMember 2019-12-31 0001522767 MRMD:MortgageMember MRMD:SouthPorteBankIllinoisPropertyMember 2020-06-30 0001522767 MRMD:MortgageMember MRMD:SouthPorteBankIllinoisPropertyMember 2019-12-31 0001522767 MRMD:MortgageMember 2020-06-30 0001522767 MRMD:MortgageMember 2019-12-31 0001522767 MRMD:MortgageAgreementMember 2017-11-01 2017-11-30 0001522767 MRMD:MortgageAgreementMember MRMD:NewBedfordMassachusettsMember 2017-11-30 0001522767 MRMD:MortgageAgreementMember us-gaap:PrimeRateMember 2017-11-01 2017-11-30 0001522767 MRMD:MortgageAgreementMember MRMD:FloorRateMember 2017-11-01 2017-11-30 0001522767 MRMD:MortgageAgreementMember us-gaap:PrimeRateMember MRMD:MayTwoTwoThousandNineteenMember 2017-11-01 2017-11-30 0001522767 MRMD:MortgageAgreementMember MRMD:FloorRateMember MRMD:MayTwoTwoThousandNineteenMember 2017-11-01 2017-11-30 0001522767 MRMD:MortgageAgreementMember us-gaap:PrimeRateMember MRMD:MayTwoTwoThousandTwentyFourMember 2017-11-01 2017-11-30 0001522767 MRMD:MortgageAgreementMember MRMD:FloorRateMember MRMD:MayTwoTwoThousandTwentyFourMember 2017-11-01 2017-11-30 0001522767 MRMD:MortgageAgreementMember 2020-06-30 0001522767 MRMD:MortgageAgreementMember 2019-12-31 0001522767 MRMD:MortgageAgreementMember country:DE 2017-11-30 0001522767 MRMD:MortgageAgreementMember country:DE 2017-11-01 2017-11-30 0001522767 MRMD:MortgageAgreementMember country:DE MRMD:SeptemberTwoThousandTwentyOneMember 2017-11-01 2017-11-30 0001522767 MRMD:MortgageAgreementMember country:DE us-gaap:PrimeRateMember 2017-11-01 2017-11-30 0001522767 MRMD:MortgageAgreementMember country:DE MRMD:FloorRateMember 2017-11-01 2017-11-30 0001522767 MRMD:MortgageAgreementMember country:DE 2020-06-30 0001522767 MRMD:MortgageAgreementMember country:DE 2019-12-31 0001522767 MRMD:MortgageAgreementMember MRMD:DuQuoinStateBankMember 2016-05-31 0001522767 MRMD:MortgageAgreementMember MRMD:DuQuoinStateBankMember 2016-05-01 2016-05-31 0001522767 MRMD:MortgageAgreementMember MRMD:DuQuoinStateBankMember 2020-06-30 0001522767 MRMD:MortgageAgreementMember MRMD:DuQuoinStateBankMember 2019-12-31 0001522767 MRMD:MortgageAgreementMember MRMD:SouthPorteBankMember 2020-02-01 2020-02-29 0001522767 MRMD:ExchangeAgreementMember MRMD:FourPointFourMillionNotesMember 2020-02-29 0001522767 MRMD:ExchangeAgreementMember MRMD:FourPointFourMillionNotesMember 2020-02-01 2020-02-29 0001522767 MRMD:ExchangeAgreementMember MRMD:FourPointFourMillionNotesMember 2020-06-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:MariMedHempIncMember MRMD:TenMillionNoteMember 2019-06-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:MariMedHempIncMember MRMD:TenMillionNoteMember 2020-01-01 2020-01-31 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:MariMedHempIncMember MRMD:TenMillionNoteMember 2019-01-01 2019-12-31 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:MariMedHempIncMember MRMD:TenMillionNoteMember 2019-12-31 0001522767 MRMD:PromissoryNoteMember MRMD:ElevenPointFiveMillionNoteMember 2020-02-27 2020-02-29 0001522767 MRMD:PromissoryNoteMember MRMD:ElevenPointFiveMillionNoteMember 2020-02-29 0001522767 MRMD:PromissoryNoteMember MRMD:ElevenPointFiveMillionNoteMember srt:MinimumMember 2020-02-27 2020-02-29 0001522767 MRMD:SecondAmendmentAgreementMember MRMD:ElevenPointFiveMillionNoteMember 2020-06-30 0001522767 MRMD:SecondAmendmentAgreementMember MRMD:ElevenPointFiveMillionNoteMember 2020-06-01 2020-06-30 0001522767 MRMD:SecondAmendmentAgreementMember MRMD:EightPointEightMillionNoteMember 2020-06-30 0001522767 MRMD:SecondAmendmentAgreementMember MRMD:TwentyOneMillionHolderMember 2020-06-01 2020-06-30 0001522767 MRMD:SecondAmendmentAgreementMember MRMD:EightPointEightMillionNoteMember 2020-06-19 2020-06-20 0001522767 MRMD:SecondAmendmentAgreementMember MRMD:EightPointEightMillionNoteMember 2020-06-20 0001522767 us-gaap:SubsequentEventMember MRMD:EightPointEightMillionNoteMember srt:MinimumMember 2020-07-01 2020-07-31 0001522767 2020-07-01 2020-07-31 0001522767 us-gaap:SubsequentEventMember MRMD:EightPointEightMillionNoteMember srt:MaximumMember 2020-07-01 2020-07-31 0001522767 us-gaap:SubsequentEventMember MRMD:EightPointEightMillionNoteMember 2020-07-31 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:MariMedHempIncMember MRMD:GenCannaMember MRMD:ThirtyThousandFeeMember 2019-04-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:MariMedHempIncMember MRMD:GenCannaMember MRMD:ThirtyThousandFeeMember 2019-04-01 2019-04-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:MariMedHempIncMember MRMD:NoteHolderMember MRMD:ThirtyThousandFeeMember 2019-04-01 2019-04-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:MariMedHempIncMember MRMD:NoteHolderMember 2020-06-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:MariMedHempIncMember MRMD:NoteHolderMember 2020-01-01 2020-06-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:SixMillionNoteMember 2019-01-01 2019-03-31 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:SixMillionNoteMember 2019-06-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:SixMillionNoteMember 2019-12-01 2019-12-31 0001522767 MRMD:ExtensionAgreementMember MRMD:SixMillionNoteMember 2020-04-30 0001522767 MRMD:ExtensionAgreementMember MRMD:SixMillionNoteMember 2020-04-01 2020-04-30 0001522767 MRMD:ExtensionAgreementMember MRMD:NineHundredKNoteMember 2020-04-01 2020-04-30 0001522767 MRMD:ExtensionAgreementMember MRMD:NineHundredKNoteMember 2020-06-30 0001522767 us-gaap:SubsequentEventMember MRMD:ExtensionAgreementMember MRMD:NineHundredKNoteMember 2020-07-31 0001522767 MRMD:ExtensionAgreementMember 2020-06-01 2020-06-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:ThreeMillionNoteMember 2018-09-01 2018-09-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:ThreeMillionNoteMember 2020-06-30 0001522767 MRMD:PromissoryNotesMember MRMD:ThreeMillionNoteMember 2019-01-01 2019-12-31 0001522767 MRMD:PromissoryNotesMember MRMD:ThreeMillionNoteMember 2018-09-30 0001522767 MRMD:PromissoryNotesMember MRMD:ThreeMillionNoteMember 2018-09-01 2018-12-31 0001522767 MRMD:PromissoryNotesMember MRMD:ThreeMillionNoteMember 2020-06-30 0001522767 MRMD:PromissoryNotesMember MRMD:ThreeMillionNoteMember 2019-12-31 0001522767 MRMD:PromissoryNotesMember MRMD:IndividualsAndAccreditedInvestorsMember 2020-01-01 2020-06-30 0001522767 MRMD:PromissoryNotesMember MRMD:IndividualsAndAccreditedInvestorsMember 2019-01-01 2019-12-31 0001522767 MRMD:PromissoryNotesMember MRMD:IndividualsAndAccreditedInvestorsMember srt:MinimumMember 2019-01-01 2019-12-31 0001522767 MRMD:PromissoryNotesMember MRMD:IndividualsAndAccreditedInvestorsMember srt:MaximumMember 2019-01-01 2019-12-31 0001522767 MRMD:PromissoryNotesMember MRMD:IndividualsAndAccreditedInvestorsMember 2020-02-01 2020-02-29 0001522767 MRMD:PromissoryNotesMember MRMD:IndividualsAndAccreditedInvestorsMember 2020-06-30 0001522767 us-gaap:SubsequentEventMember MRMD:ThirdPartyNotesMember 2020-07-01 2020-07-31 0001522767 MRMD:ConvertibleDebenturesOneMember 2020-01-01 2020-06-30 0001522767 MRMD:ConvertibleDebenturesOneMember 2020-06-30 0001522767 MRMD:ConvertibleDebenturesTwoMember 2020-01-01 2020-06-30 0001522767 MRMD:ConvertibleDebenturesTwoMember 2020-06-30 0001522767 MRMD:ConvertibleDebenturesThreeMember 2020-01-01 2020-06-30 0001522767 MRMD:ConvertibleDebenturesThreeMember 2020-06-30 0001522767 MRMD:ConvertibleDebenturesFourMember 2020-01-01 2020-06-30 0001522767 MRMD:ConvertibleDebenturesFourMember 2020-06-30 0001522767 MRMD:ConvertibleDebenturesFiveMember 2020-01-01 2020-06-30 0001522767 MRMD:ConvertibleDebenturesFiveMember 2020-06-30 0001522767 MRMD:ConvertibleDebenturesSixMember 2020-01-01 2020-06-30 0001522767 MRMD:ConvertibleDebenturesSixMember 2020-06-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember 2018-10-01 2018-11-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember 2018-11-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember MRMD:WarrantsMember 2018-11-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember MRMD:WarrantsMember srt:MinimumMember 2018-11-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember MRMD:WarrantsMember srt:MaximumMember 2018-11-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember 2020-06-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember 2020-03-31 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember 2020-01-01 2020-03-31 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember 2020-01-01 2020-06-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:HolderMember 2020-06-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:HolderMember 2019-02-01 2020-06-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:HolderMember srt:MinimumMember 2020-06-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:HolderMember srt:MaximumMember 2020-06-30 0001522767 MRMD:ConvertibleDebenturesMember 2020-06-30 0001522767 MRMD:ConvertibleDebenturesMember 2020-01-01 2020-06-30 0001522767 MRMD:ConvertibleDebenturesMember srt:MinimumMember 2020-06-30 0001522767 MRMD:ConvertibleDebenturesMember srt:MaximumMember 2020-06-30 0001522767 MRMD:ConvertibleDebenturesMember 2019-01-01 2019-06-30 0001522767 MRMD:TwentyOneMillionHolderMember 2020-06-30 0001522767 MRMD:TwentyOneMillionHolderMember 2019-12-31 0001522767 MRMD:ExchangeAgreementMember MRMD:TwoInstitutionalShareholdersMember MRMD:SeriesBConvertiblePreferredStockMember 2020-02-28 2020-02-29 0001522767 MRMD:ExchangeAgreementMember MRMD:TwoInstitutionalShareholdersMember MRMD:TwoPromissoryNotesMember 2020-02-29 0001522767 MRMD:SeriesBHoldersMember 2020-02-29 0001522767 MRMD:SeriesBHoldersMember 2020-02-28 2020-02-29 0001522767 MRMD:SeriesBConvertiblePreferredStockMember MRMD:VolumeWeightedAveragepriceOfCommonStockMember 2020-02-28 2020-02-29 0001522767 MRMD:ExchangeAgreementMember MRMD:TwoInstitutionalShareholdersMember MRMD:SeriesBConvertiblePreferredStockMember 2020-02-29 0001522767 MRMD:CurrentEmployeeMember 2020-01-01 2020-06-30 0001522767 MRMD:PreviouslyIssuedSubscriptionMember 2020-01-01 2020-06-30 0001522767 MRMD:PreviouslyIssuedSubscriptionMember 2019-01-01 2019-06-30 0001522767 MRMD:KPGOfAnnaLLCAndMariHoldingsMDLLCMember 2019-01-01 2019-12-31 0001522767 MRMD:TheHarvestFoundationLLCMember 2019-01-01 2019-12-31 0001522767 MRMD:MeditaurusLLCMember 2019-01-01 2019-12-31 0001522767 MRMD:TerraceIncMember 2019-01-01 2019-12-31 0001522767 MRMD:CVPWorldwideLLCMember 2018-01-01 2018-12-31 0001522767 MRMD:PromissoryNoteMember 2020-01-01 2020-06-30 0001522767 MRMD:TwentyOneMillionHoldersMember 2020-06-30 0001522767 MRMD:TwentyOneMillionHoldersMember 2020-01-01 2020-06-30 0001522767 MRMD:TwentyOneMillionHoldersMember 2019-01-01 2019-06-30 0001522767 MRMD:StockOptionsMember 2019-01-01 2019-06-30 0001522767 us-gaap:WarrantMember 2019-06-30 0001522767 MRMD:CommonStockIssuanceObligationsMember 2020-01-01 2020-06-30 0001522767 MRMD:IncentivePlanMember 2019-08-31 0001522767 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001522767 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2020-01-01 2020-06-30 0001522767 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001522767 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2019-06-30 0001522767 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2019-06-30 0001522767 MRMD:CashlessBasisMember 2019-01-01 2019-06-30 0001522767 MRMD:RangeOneMember 2020-06-30 0001522767 MRMD:RangeOneMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeTwoMember 2020-06-30 0001522767 MRMD:RangeTwoMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeThreeMember 2020-06-30 0001522767 MRMD:RangeThreeMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeFourMember 2020-06-30 0001522767 MRMD:RangeFourMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeFiveMember 2020-06-30 0001522767 MRMD:RangeFiveMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeSixMember 2020-06-30 0001522767 MRMD:RangeSixMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeSevenMember 2020-06-30 0001522767 MRMD:RangeSevenMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeEightMember 2020-06-30 0001522767 MRMD:RangeEightMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeNineMember 2020-06-30 0001522767 MRMD:RangeNineMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeTenMember 2020-06-30 0001522767 MRMD:RangeTenMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeElevenMember 2020-06-30 0001522767 MRMD:RangeElevenMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeTwelveMember 2020-06-30 0001522767 MRMD:RangeTwelveMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeThirteenMember 2020-06-30 0001522767 MRMD:RangeThirteenMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeFourteenMember 2020-06-30 0001522767 MRMD:RangeFourteenMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeFifteenMember 2020-06-30 0001522767 MRMD:RangeFifteenMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeSixteenMember 2020-06-30 0001522767 MRMD:RangeSixteenMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeSeventeenMember 2020-06-30 0001522767 MRMD:RangeSeventeenMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeEighteenMember 2020-06-30 0001522767 MRMD:RangeEighteenMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeNineteenMember 2020-06-30 0001522767 MRMD:RangeNineteenMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeTwentyMember 2020-06-30 0001522767 MRMD:RangeTwentyMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeTwentyTwoMember 2020-06-30 0001522767 MRMD:RangeTwentyOneMember 2020-06-30 0001522767 MRMD:RangeTwentyOneMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeTwentyTwoMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeTwentyThreeMember 2020-06-30 0001522767 MRMD:RangeTwentyThreeMember 2020-01-01 2020-06-30 0001522767 MRMD:RangeTwentyFourMember 2020-06-30 0001522767 MRMD:RangeTwentyFourMember 2020-01-01 2020-06-30 0001522767 MRMD:SecondAmendmentAgreementMember MRMD:EightPointEightMillionNoteMember 2020-01-01 2020-06-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember 2019-01-01 2019-06-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember 2019-06-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:MariMedHempIncMember MRMD:TenMillionNoteMember 2019-01-01 2019-06-30 0001522767 us-gaap:WarrantMember srt:MinimumMember 2019-06-30 0001522767 us-gaap:WarrantMember srt:MaximumMember 2019-06-30 0001522767 us-gaap:WarrantMember 2019-01-01 2019-06-30 0001522767 MRMD:WarrantOneMember 2019-06-30 0001522767 MRMD:WarrantOneMember srt:MinimumMember 2020-06-30 0001522767 MRMD:WarrantOneMember srt:MaximumMember 2020-06-30 0001522767 us-gaap:RealEstateMember 2020-01-01 2020-06-30 0001522767 us-gaap:RealEstateMember 2019-01-01 2019-06-30 0001522767 us-gaap:ManagementServiceMember 2020-01-01 2020-06-30 0001522767 us-gaap:ManagementServiceMember 2019-01-01 2019-06-30 0001522767 MRMD:SupplyProcurementMember 2020-01-01 2020-06-30 0001522767 MRMD:SupplyProcurementMember 2019-01-01 2019-06-30 0001522767 us-gaap:LicenseAndServiceMember 2020-01-01 2020-06-30 0001522767 us-gaap:LicenseAndServiceMember 2019-01-01 2019-06-30 0001522767 MRMD:ProductSalesMember 2020-01-01 2020-06-30 0001522767 MRMD:ProductSalesMember 2019-01-01 2019-06-30 0001522767 us-gaap:RevenueFromContractWithCustomerMember MRMD:TwoClientsMember 2020-01-01 2020-06-30 0001522767 us-gaap:RevenueFromContractWithCustomerMember MRMD:TwoClientsMember 2019-01-01 2019-06-30 0001522767 MRMD:GenCannaGlobalIncMember 2020-06-30 0001522767 MRMD:HarvestFoundationLLCMember 2020-06-30 0001522767 MRMD:GenCannaMember 2019-01-01 2019-12-31 0001522767 MRMD:GenCannaMember 2019-12-31 0001522767 MRMD:GenCannaMember MRMD:RelatedPartyMember 2019-01-01 2019-12-31 0001522767 MRMD:ThreeIndependentBoardMembersMember 2019-01-01 2019-12-31 0001522767 MRMD:ThreeIndependentBoardMembersMember srt:MaximumMember 2019-01-01 2019-12-31 0001522767 MRMD:ThreeIndependentBoardMembersMember 2019-12-31 0001522767 MRMD:OptionsOneMember MRMD:CEOAndIndependentBoardMemberMember 2019-01-01 2019-12-31 0001522767 us-gaap:CommonStockMember MRMD:CEOAndIndependentBoardMemberMember 2019-01-01 2019-12-31 0001522767 MRMD:OptionsOneMember MRMD:CEOAndIndependentBoardMemberMember srt:MinimumMember 2019-12-31 0001522767 MRMD:OptionsOneMember MRMD:CEOAndIndependentBoardMemberMember srt:MaximumMember 2019-12-31 0001522767 MRMD:TwoBoardMembersMember 2019-01-01 2019-12-31 0001522767 2018-08-01 2018-08-31 0001522767 MRMD:CEOandCFOMember 2020-06-30 0001522767 MRMD:CEOandCFOMember 2019-12-31 0001522767 MRMD:CEOandCFOMember MRMD:PartiallyOwnedCompaniesMember 2020-06-30 0001522767 MRMD:CEOandCFOMember MRMD:PartiallyOwnedCompaniesMember 2019-12-31 0001522767 MRMD:TwoStockholdersMember 2019-12-31 0001522767 country:DE MRMD:OperatingLeaseCommitmentsMember 2016-10-31 0001522767 country:DE MRMD:OperatingLeaseCommitmentsMember 2016-10-01 2016-10-31 0001522767 country:DE 2019-06-30 0001522767 country:DE 2019-06-29 2019-06-30 0001522767 country:DE 2020-06-29 2020-06-30 0001522767 stpr:NV 2020-06-30 0001522767 stpr:NV 2020-01-01 2020-06-30 0001522767 country:MA 2020-06-30 0001522767 country:MA 2020-01-01 2020-06-30 0001522767 country:MD MRMD:OperatingLeaseCommitmentsMember 2020-06-30 0001522767 country:MD MRMD:OperatingLeaseCommitmentsMember 2020-01-01 2020-06-30 0001522767 MRMD:FinanceLeaseCommitmentsMember MRMD:MachineryMember 2020-01-01 2020-06-30 0001522767 MRMD:LeaseCommitmentsMember 2020-06-30 0001522767 MRMD:OperatingLeasesMember 2020-06-30 0001522767 MRMD:FinancingLeasesMember 2020-06-30 0001522767 MRMD:TerminatedEmploymentAgreementMember 2020-06-30 0001522767 MRMD:TerminatedEmploymentAgreementMember 2019-12-31 0001522767 MRMD:MarylandAcquisitionMember 2019-11-10 2019-11-13 0001522767 MRMD:TwentyOneMillionDebenturesMember 2020-05-01 2020-05-28 0001522767 MRMD:TwentyOneMillionDebenturesMember 2020-04-30 0001522767 MRMD:TwentyOneMillionDebenturesMember 2020-05-28 0001522767 MRMD:CurrentEmployeesMember 2020-05-01 2020-05-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft MRMD:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period ended June 30, 2020

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________________ to __________________

 

Commission File number 0-54433

 

MARIMED INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   27-4672745
(State or Other Jurisdiction of   (I.R.S. Employer
Incorporation or Organization)   Identification No.)

 

10 Oceana Way

Norwood, MA 02062

(Address of Principal Executive Offices)

 

617-795-5140

(Registrant’s Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Title of each class   Ticker symbol(s)   Name of each exchange on which registered
Not Applicable.   Not Applicable.   Not Applicable.

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated filer ☐ Accelerated filer ☒
Non-accelerated filer ☐ Smaller reporting company
  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of August 10, 2020, 276,696,552 shares of the registrant’s common stock were outstanding.

 

 

 

 
 

 

MariMed Inc.

Table of Contents

 

    Page
  PART I – FINANCIAL INFORMATION  
     
Item 1. Financial Statements  
     
  Condensed Consolidated Balance Sheets as of June 30, 2020 (Unaudited) and December 31, 2019 3
     
  Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2020 and 2019 (Unaudited) 4
     
  Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the Six Months Ended June 30, 2020 and 2019 (Unaudited) 5
     
  Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2020 and 2019 (Unaudited) 6
     
  Notes to Condensed Consolidated Financial Statements (Unaudited) 7
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 38
     
Item 3. Quantitative and Qualitative Disclosure About Market Risk 46
     
Item 4. Controls and Procedures 46
     
  PART II – OTHER INFORMATION  
     
Item 1. Legal Proceedings 47
     
Item 1A. Risk Factors 47
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 47
     
Item 3. Defaults Upon Senior Securities 47
     
Item 4. Mine Safety Disclosures 47
     
Item 5. Other Information 47
     
Signatures 50

 

2

 

 

MariMed Inc.

Condensed Consolidated Balance Sheets

 

   June 30,
2020
   December 31,
2019
 
   (Unaudited)     
Assets        
Current assets:          
Cash and cash equivalents  $2,339,610   $738,688 
Accounts receivable, net   2,873,505    1,669,139 
Deferred rents receivable   1,990,289    1,796,825 
Due from third parties, net   198,680    - 
Notes receivable, current portion   316,936    311,149 
Inventory   3,905,963    1,219,429 
Investments   785,285    1,449,144 
Other current assets   209,101    192,368 
Total current assets   12,619,369    7,376,742 
           
Property and equipment, net   44,622,081    42,792,369 
Intangibles, net   2,452,134    2,364,042 
Investments   1,034,017    1,324,661 
Notes receivable, less current portion   1,309,729    1,639,496 
Right-of-use assets under operating leases   5,514,031    5,787,423 
Right-of-use assets under finance leases   94,761    111,103 
Other assets   185,905    175,905 
Total assets  $67,832,027   $61,571,741 
           
Liabilities, mezzanine equity, and stockholders’ equity (deficit)          
Current liabilities:          
Accounts payable  $4,586,897   $4,719,069 
Accrued expenses   3,002,216    5,395,996 
Notes payable, current portion   17,210,101    23,112,742 
Mortgages payable, current portion   1,166,259    223,888 
Debentures payable, current portion   4,476,667    - 
Operating lease liabilities, current portion   988,305    917,444 
Finance lease liabilities, current portion   38,412    38,412 
Due to related parties   1,391,309    1,454,713 
Other current liabilities   1,254,412    858,176 
Total current liabilities   34,114,578    36,720,440 
           
Notes payable, less current portion   11,190,177    - 
Mortgages payable, less current portion   6,965,319    7,112,842 
Debentures payable, less current portion   

-

    5,835,212 
Operating lease liabilities, less current portion   5,106,204    5,399,414 
Finance lease liabilities, less current portion   60,240    75,413 
Other liabilities   100,200    100,200 
Total liabilities   57,536,718    55,243,521 
           
Mezzanine equity:          
Series B convertible preferred stock, $0.001 par value; 4,908,333 and zero shares authorized, issued and outstanding at June 30, 2020 and December 31, 2019, respectively   14,725,000    - 
           
Stockholders’ equity (deficit):          
Series A convertible preferred stock, $0.001 par value; zero and 50,000,000 shares authorized at June 30, 2020 and December 31, 2019, respectively; zero shares issued and outstanding at June 30, 2020 and December 31, 2019   -    - 
No designation preferred stock, $0.001 par value; 45,091,667 and zero shares authorized at June 30, 2020 and December 31, 2019, respectively; zero shares issued and outstanding at June 30, 2020 and December 31, 2019   -    - 
Common stock, $0.001 par value; 500,000,000 shares authorized at June 30, 2020 and December 31, 2019; 271,479,247 and 228,408,024 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively   271,479    228,408 
Common stock subscribed but not issued; 34,171 and 3,236,857 shares at June 30, 2020 and December 31, 2019, respectively   5,365    1,168,074 
Additional paid-in capital   106,253,357    112,245,730 
Accumulated deficit   (110,396,008)   (106,760,527)
Noncontrolling interests   (563,884)   (553,465)
Total stockholders’ equity (deficit)   (4,429,691)   6,328,220 
Total liabilities, mezzanine equity, and stockholders’ equity (deficit)  $67,832,027   $61,571,741 

 

See accompanying notes to condensed consolidated financial statements.

 

3

 

 

MariMed Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

 

   2020   2019   2020   2019 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2020   2019   2020   2019 
                 
Revenues  $9,610,306   $3,657,798   $17,076,325   $7,173,614 
Revenues from related party   -    22,014,878    -    22,014,878 
Total revenues   9,610,306    25,672,676    17,076,325    29,188,492 
                     
Cost of revenues   3,452,169    16,745,553    6,050,086    18,000,343 
                     
Gross profit   6,158,137    8,927,123    11,026,239    11,188,149 
                     
Operating expenses:                    
Personnel   1,207,141    825,130    2,720,524    1,498,504 
Marketing and promotion   65,618    76,060    178,002    194,959 
General and administrative   2,336,102    2,676,454    4,584,037    4,357,476 
Bad debts   450,000    

-

    450,000    - 
Total operating expenses   4,058,861    3,577,644    7,932,563    6,050,939 
                     
Operating income   2,099,276    5,349,479    3,093,676    5,137,210 
                     
Non-operating income (expenses):                    
Interest expense   (2,969,191)   (2,619,460)   (5,660,336)   (4,560,007)
Interest income   40,863    64,345    86,894    346,754 
Loss on obligations settled with equity   (44,678)   -    (44,678)   - 
Equity in earnings of investments   (32,958)   (45,465)   (32,958)   1,912,942 
Change in fair value of investments   (234,544)   -    (921,546)   -  
Other   -    2,948,917    -    2,948,917 
Total non-operating income (expenses), net   (3,240,508)   348,337    (6,572,624)   648,606 
                     
Income (loss) before income taxes   (1,141,232)   5,697,816    (3,478,948)   5,785,816 
Provision for income taxes   -    974,584    -    984,595 
Net income (loss)  $(1,141,232)  $4,723,232   $(3,478,948)  $4,801,221 
                     
Net income (loss) attributable to noncontrolling interests  $72,805   $46,147   $156,533   $147,346 

Net income (loss) attributable to

MariMed Inc.

  $(1,214,037)  $4,677,085   $(3,635,481)  $4,653,875 
                     
Net income (loss) per share                    
Basic  $(0.00)  $0.02   $(0.02)  $0.02 
Diluted  $(0.00)  $0.02   $(0.02)  $0.02 
                     
Weighted average common shares outstanding                    
Basic   247,990,403    213,319,149    240,664,873    211,510,986 
Diluted   247,990,403    232,828,964    240,664,873    231,020,801 

 

See accompanying notes to condensed consolidated financial statements.

 

4

 

 

MariMed Inc.

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(Unaudited)

 

   Shares   Par Value   Shares   Amount   Capital   Deficit   Interests   Equity 
   Common Stock   Common Stock Subscribed But Not Issued   Additional Paid-In   Accumulated   Non-Controlling   Total Stockholders’ 
   Shares   Par Value   Shares   Amount   Capital   Deficit   Interests   Equity 
Balances at December 31, 2018   211,013,043   $211,013    97,136   $169,123   $87,180,165   $(25,575,808)  $(220,032)  $61,764,461 
Sales of common stock   799,995    800    -    -    2,599,200    -    -    2,600,000 
Issuance of subscribed shares   97,136    97    (97,136)   (169,123)   169,026    -    -    - 
MediTaurus acquisition   -    -    752,260    2,080,000    -    -    1,200,000    3,280,000 
Terrace investment   500,000    500    -    -    1,589,500    -    -    1,590,000 
Harvest payment   1,000,000    1,000    -    -    (1,000)   -    -    - 
Exercise of options   358,446    

359

              12,641              13,000 
Exercise of warrants   666,104    666    -    -    601,776    -    -    602,442 
Amortization of option and warrant issuances   -    -    -    -    2,458,941    -    -    2,458,941 
Beneficial conversion feature on debentures   -    -    -    -    3,384,980    -    -    3,384,980 
Conversion of debentures payable   1,156,379    1,156    -    -    2,626,601    -    -    2,627,754 
Distributions   -    -    -    -    -    -    (297,369)   (297,369)
Net income (loss)   -    -    -    -    -    4,653,875    147,346    4,801,221 
Balances at June 30, 2019   215,591,103   $ 215,591    752,260   $ 2,080,000   $ 100,621,830   $ (20,921,933)  $829,945   $82,825,433 

 

   Common Stock   Common Stock Subscribed But Not Issued   Additional Paid-In   Accumulated    Non-
Controlling
   Total Stockholders’
Equity
 
   Shares   Par Value   Shares   Amount   Capital   Deficit   Interests   (Deficit) 
Balances at December 31, 2019   228,408,024   $ 228,408    3,236,857   $ 1,168,074   $ 112,245,730   $ (106,760,527)  $ (553,465)   6,328,220 
Issuance of subscribed shares   3,236,857    3,237    (3,236,857)   (1,168,074)   1,164,837    -    -    - 
Stock grants   30,307    30     34,171     5,365    5,335    -    -    10,730 
Amortization of option grants   -    -    -    -    

556,379

    -    -    

556,379

 
Issuance of warrants attached to debt   -    -    -    -    

65,931

    -    -    

65,931

Discount on debentures payable   -    -    -    -    28,021    -    -    28,021 
Beneficial conversion feature on debentures payable   -    -    -    -    379,183    -    -    379,183 
Conversion of debentures payable   35,886,796    35,887    -    -    4,981,208    -    -    5,017,095 
Conversion of common stock to preferred stock   (4,908,333)   (4,908)   -    -    (14,720,092)   -    -    (14,725,000)
Conversion of promissory note   

2,525,596

    

2,525

    -    -    

457,525

    -    -    

460,050

 
Extinguishment of promissory note   

1,900,000

    

1,900

    -    -    

350,100

    -    -    

352,000

Common stock issued to settle obligations   

4,400,000

    

4,400

    -    -    

739,200

    -    -    

743,600

 
Distributions   -    -    -    -    -    -    (166,952)   

(166,952

)
Net income (loss)   -    -    -    -    -    

(3,635,481

)   156,533     (3,478,948)
Balances at June 30, 2020   271,479,247   $271,479    34,171   $5,365    $106,253,357   $(110,396,008  $(563,884)  $(4,429,691

 

The above statements do not show columns for Series A convertible preferred stock and undesignated

preferred stock as the balances were zero and there was no activity in the periods presented.

See accompanying notes to condensed consolidated financial statements.

 

5

 

 

MariMed Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

   2020   2019 
   Six Months Ended June 30, 
   2020   2019 
Cash flows from operating activities:          
Net income (loss) attributable to MariMed Inc.  $(3,635,481)  $4,653,875 
Net income (loss) attributable to noncontrolling interests   156,533    147,346 
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:          
Depreciation   907,285    448,935 
Amortization of intangibles   166,908    107,917 
Amortization of stock grants   10,730    - 
Amortization of option grants   556,379    929,597 
Amortization of warrants attached to debt   498,694    1,014,379 
Amortization of beneficial conversion feature   2,170,401    2,281,687 
Amortization of original issue discount   241,613    28,920 
Bad debt expense   450,000    - 
Loss on obligations settled with equity    44,678    - 
Equity in earnings of investments   32,958    (1,912,941)
Change in fair value of investments   921,546    - 
Changes in operating assets and liabilities:          
Accounts receivable, net   (1,654,366)   (3,279,717)
Accounts receivable from related party, net   -    (25,177,845)
Deferred rents receivable   (193,464)   48,470 
Due from third parties   (198,680)   141,783 
Inventory   (2,686,534)   (4,263,846)
Other current assets   (16,733)   48,823 
Other assets   (10,000)   (262,981)
Accounts payable   566,749    (1,746,067)
Accrued expenses   1,759,330    1,652,508 
Deferred rents payable   -    (105,901)
Operating lease payments   51,043    267,253 
Finance lease interest payments   4,033    (1,824)
Unearned revenue from related party   -    3,162,967 
Other current liabilities   396,236    - 
Other liabilities   -    (238,000)
Net cash provided by (used in) operating activities   539,858    (22,054,662)
           
Cash flows from investing activities:          
Purchase of property and equipment   (2,720,655)   (3,946,208)
Purchase of cannabis licenses   (255,000)   - 
Investment in notes receivable   -    (1,550,000)
Interest on notes receivable   406,670    117,006 
MediTaurus acquisition   -    (171,003)
Due from related parties   -    119,781 
Net cash used in investing activities   (2,568,985)   (5,430,424)
           
Cash flows from financing activities:          
Issuance of common stock   -    2,600,000 
Issuance of promissory notes   5,249,763    17,000,000 
Repayments of promissory notes   (3,100,000)   - 
Proceeds from issuance of debentures   935,000    7,275,000 
Proceeds from mortgages   

907,200

    - 
Payments on mortgages   (112,352)   (79,012)
Exercise of stock options   -    13,000 
Exercise of warrants   -    602,442 
Due to related parties   (63,404)   (199,154)
Finance lease principal payments   (19,206)   (3,923)
Distributions   (166,952)   (297,369)
Net cash provided by financing activities   3,630,049    26,910,984 
           
Net change to cash and cash equivalents   1,600,922    (574,102)
Cash and cash equivalents at beginning of period   738,688    4,104,315 
Cash and cash equivalents at end of period  $2,339,610   $3,530,213 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $703,571   $787,028 
Cash paid for income taxes  $

13,000

   $10,011 
           
Non-cash activities:          
Conversions of debentures payable  $

5,017,095

   $2,626,759 
Beneficial conversion feature on debentures payable  $

379,183

   $3,384,980 
Discount on debentures payable  $28,021   $928,724 
Issuance of common stock associated with subscriptions  $

1,168,074

   $

169,123

 
Discount on promissory notes  $

65,931

   $

600,621

 
Conversion of promissory notes  $

460,050

   $- 
Extinguishment of promissory note  $

352,000

   $- 
Common stock issued to settle obligations  $

698,922

   $- 
Exchange of common stock to preferred stock  $14,725,000   $- 
Conversion of accrued interest to promissory note  $3,908,654   $- 
Conversion of debentures receivable to investment  $-   $30,000,000 
Operating lease right-of-use assets and liabilities  $-   $6,981,772 
Finance lease right-of-use assets and liabilities  $-   $77,773 
Conversion of notes receivable to investment  $-   $257,687 
Conversion of advances to notes receivable  $-   $855,913 
MediTaurus acquisition  $-   $2,500,000 
Terrace investment  $-   $1,590,000 
Harvest payment  $-   $1,000 

 

See accompanying notes to condensed consolidated financial statements.

 

6

 

 

MariMed Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

 

MariMed Inc. (the “Company”) is a multi-state operator in the cannabis industry. The Company is an expert in the development, operation, management, and optimization of facilities for the cultivation, production and dispensing of medicinal and recreational cannabis and cannabis-infused products. To date, the Company has developed in excess of 300,000 square feet of state-of-the-art, regulatory-compliant facilities.

 

At the outset of the Company’s entrance into the cannabis industry, the Company provided advisory services and assistance to its clients in the procurement of state-issued cannabis licenses, leased its cannabis facilities to these newly-licensed clients, and provided industry-leading expertise and oversight in all aspects of their cannabis operations, as well as ongoing regulatory, accounting, human resources, and administrative services. Since this time, the Company successfully secured 19 cannabis licenses across six states—two in Delaware, five in Illinois, three in Maryland, six in Massachusetts, two in Nevada, and one in Rhode Island.

 

The Company has demonstrated an excellent track record developing and operating licensed cannabis facilities, and implementing its proprietary operating procedures and industry best practices. In 2018, the Company commenced a strategic plan to transition from an advisory business that provides cannabis licensing, operational consulting and real estate services, to a direct owner of cannabis licenses and operator of seed-to-sale operations, dedicated to the improvement of health and wellness through the use of cannabinoids and cannabis products.

 

The Company’s strategic plan consists of the acquisition of its cannabis-licensed clients located in five states—Delaware, Illinois, Maryland, Massachusetts, and Nevada—and the consolidation of these entities under the MariMed banner. The Company has played a key role in the successes of these entities, from the securing of their cannabis licenses, to the development of facilities that are models of excellence, to providing operational and corporate guidance. Accordingly, the Company believes it is well suited to own these facilities and manage the continuing growth of their operations.

 

A goal in completing this transition is to present a simpler, more transparent financial picture to the investment community. Once the consolidation is complete, the Company’s financial statements will provide a clearer representation of the revenues, earnings, and other financial metrics that the Company is generating, and a reflection of the full breadth of the Company’s overall business.

 

To date, acquisitions of the licensed businesses in Massachusetts and Illinois have been state-approved and completed, and establishes the Company as a fully integrated seed-to-sale multi-state operator. The acquisitions of the remaining entities located in Delaware, Maryland, and Nevada are at various stages of completion and subject to each state’s laws governing the ownership and transfer of cannabis licenses, which in the case of Delaware requires a modification of current cannabis ownership laws to permit for-profit ownership. However, the Company continues to develop additional revenue and business in these states and plans to leverage its success to expand into other markets where cannabis is and becomes legal.

 

The Company has also created its own brands of cannabis flower, concentrates, and precision-dosed products utilizing proprietary strains and formulations. These products are developed by the Company in cooperation with state-licensed facilities and operators who meet the Company’s strict standards, including all natural—not artificial or synthetic—ingredients. The Company licenses its product formulations only to knowledgeable manufacturing professionals who agree to adhere to the Company’s precise scientific formulations using its trademarked product recipes.

 

7

 

 

The Company’s branded products are licensed under brand names including Kalm Fusion™, Nature’s Heritage™, and Betty’s Eddies™, and are distributed in the form of dissolvable strips, tablets, powders, microwaveable popcorn, fruit chews, and with more varieties in development. The Company also has exclusive sublicensing rights in certain states to distribute the Binske® line of cannabis products crafted from premium artisan ingredients, the Healer™ line of medical full-spectrum tinctures, and the clinically-tested medicinal cannabis strains developed in Israel by Tikun Olam™. The Company intends to continue licensing and distributing its brands as well as other top brands in the Company’s current markets and in partnerships in other states markets across the country where product sale is legal.

 

In anticipation of the growing demand for hemp-derived cannabidiol (“CBD”), the Company established a wholly owned subsidiary, MariMed Hemp Inc. (“MariMed Hemp”), to market and distribute hemp-derived CBD products across several vertical markets. Prior to this, as a means of expanding into the global CBD market, the Company acquired a majority interest of MediTaurus LLC (“MediTaurus”), an entity operating in the United States and Europe that has developed proprietary CBD formulations under its Florance™ brand.

 

In March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. The spread of the virus in the United States and the measures implemented to contain it—including business shutdowns, indoor capacity restrictions, social distancing, and diminished travel—have negatively impacted the economy and have created significant volatility and disruption in financial markets. Consequently, the Company’s expansion efforts and implementation of its strategic plan have been delayed. Additionally, while the cannabis industry has been deemed an essential business and is not expected to suffer severe declines in revenue, the Company’s business, operations, financial condition, and liquidity have been adversely affected, as further discussed in the notes to the financial statements included in this report.

 

Continued disruption to the global economy may materially and adversely affect the future carrying values of certain of the Company’s assets, including inventories, accounts receivables, and intangibles, as well as negatively impact the Company’s ability to raise working capital to support its operations. The full extent to which COVID-19 and the measures to contain it will impact the Company’s business, operations financial condition, and liquidity will depend on the continued severity and duration of the COVID-19 outbreak and other future developments in response to the virus, all of which are highly uncertain at this time. As a result, the Company cannot predict the ultimate impact of COVID-19 on its operational and financial performance.

 

The Company’s stock is quoted on the OTCQX market under the ticker symbol MRMD.

 

The Company was incorporated in Delaware in January 2011 under the name Worlds Online Inc. Initially, the Company developed and managed online virtual worlds. By early 2014, this line of business effectively ceased operating and the Company pivoted into the legal cannabis industry.

 

8

 

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

 

In accordance with GAAP, interim financial statements are not required to contain all of the disclosures normally required in annual financial statements. In addition, the results of operations of interim periods may not necessarily be indicative of the results of operations to be expected for the full year. Accordingly, these interim financial statements should be read in conjunction with the Company’s most recent audited annual financial statements and accompanying notes for the year ended December 31, 2019.

 

Certain reclassifications have been made to prior periods’ data to conform to the current period presentation. These reclassifications had no effect on reported income (losses) or cash flows.

 

Going Concern

 

In connection with the preparation of its financial statements for the six months ended June 30, 2020, the Company’s management evaluated the Company’s ability to continue as a going concern in accordance with ASU 2014-15, Presentation of Financial Statements–Going Concern (Subtopic 205-40), which requires an assessment of relevant conditions or events, considered in the aggregate, that are known or reasonably knowable by management on the issuance dates of the financial statements which indicate the probable likelihood that the Company will be unable to meet its obligations as they become due within one year after the issuance date of the financial statements.

 

As part of its evaluation, management assessed known events, trends, commitments, and uncertainties, which at the time included the status of the Company’s consolidation plan, the impact of the COVID-19 pandemic on its operations, developments concerning GenCanna’s bankruptcy proceedings, recent cannabis industry investment activity, price movements of public cannabis stock, actions and/or results of certain bellwether cannabis companies, the level of cannabis investor confidence, and changes to state laws governing recreational (adult-use) and medical cannabis.

 

At June 30, 2020, the Company’s negative working capital improved to approximately $21.5 million from approximately $29.3 million at December 31, 2019. In addition, during the six months ended June 30, 2020, the Company’s operating activities provided positive cash flow of approximately $540,000, compared to approximately $22.1 million of negative cash flow used by such activities during the same period of 2019. For further discussion of the Company’s liquidity and capital resources, please refer to Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations of this Form 10-Q for the period ended June 30, 2020.

 

Subsequent to the balance sheet date, the Company refinanced the mortgage agreement secured by its Massachusetts real estate, replacing a mortgage with a remaining principal balance of approximately $4.8 million (the “Initial Mortgage”) with a $13.0 million mortgage bearing interest at a rate of 6.5% per annum that matures in August 2025. After paying off the Initial Mortgage, the Company retired approximately $7.3 million of outstanding short-term debt that bore interest at a weighted-average rate of 15% per annum.

 

9

 

 

With respect to the Company’s consolidation plan, the operations of the acquired entities in Illinois and Massachusetts have started to generate considerable liquidity and working capital for the Company. Since their acquisition in October 2019, the KPGs in Illinois have generated in excess of $2.8 million of pretax income for the Company, in part due to the legalization of adult-use cannabis in January 2020. Additionally, the KPGs have added a third dispensary in Mt. Vernon which is completing requirements to begin operations. In Massachusetts, the cultivation and production facility acquired by the Company in December 2018 has ramped up its medical grow capabilities to full capacity. Additionally, the Massachusetts Cannabis Control Commission (the “MCCC”) has given the Company final approval for adult-use cannabis production and sales. The MCCC will perform a final inspection, which the Company expects will occur in September 2020, in order for the Company to commence business in this state’s robust adult-use market.

 

As of the filing date of this report, the Company has hired an investment banking and advisory firm to explore additional opportunities to raise capital, although there is no assurance that a financing transaction will be consummated.

 

In light of the aforementioned disclosures, among other factors reviewed as part of management’s evaluation, there is a substantial doubt that the Company will be able to continue as a going concern within one year after the issuance date of these financial statements.

 

Principles of Consolidation

 

The accompanying condensed consolidated financial statements include the accounts of MariMed Inc. and the following majority-owned subsidiaries:

 

 

Subsidiary:  Percentage
Owned
MariMed Advisors Inc.   100.0%
Mia Development LLC   89.5%
Mari Holdings IL LLC   100.0%
Mari Holdings MD LLC   97.4%
Mari Holdings NV LLC   100.0%
Hartwell Realty Holdings LLC   100.0%
iRollie LLC   100.0%
ARL Healthcare Inc.   100.0%
KPG of Anna LLC   100.0%
KPG of Harrisburg LLC   100.0%
MariMed Hemp Inc.   100.0%
MediTaurus LLC   70.0%

 

Intercompany accounts and transactions have been eliminated.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts within the financial statements and disclosures thereof. Actual results could differ from these estimates or assumptions.

 

Cash Equivalents

 

The Company considers all highly liquid investments with a maturity date of three months or less to be cash equivalents. The fair values of these investments approximate their carrying values.

 

The Company’s cash and cash equivalents are maintained with recognized financial institutions located in the United States. In the normal course of business, the Company may carry balances with certain financial institutions that exceed federally insured limits. The Company has not experienced losses on balances in excess of such limits and management believes the Company is not exposed to significant risks in that regard.

 

Accounts Receivable

 

Accounts receivable consist of trade receivables and are carried at their estimated collectible amounts.

 

The Company provides credit to its clients in the form of payment terms. The Company limits its credit risk by performing credit evaluations of its clients and maintaining a reserve, if deemed necessary, for potential credit losses. Such evaluations include the review of a client’s outstanding balances with consideration towards such client’s historical collection experience, as well as prevailing economic and market conditions and other factors. Based on such evaluations, the Company maintained an allowance for doubtful accounts of approximately $40.1 million and $39.7 million at June 30, 2020 and December 31, 2019, respectively. Please refer to Note 16 – Bad Debts for further discussion on receivable reserves.

 

10

 

 

Inventory

 

Inventory is carried at the lower of cost or net realizable value, with the cost being determined on a first-in, first-out (FIFO) basis. The Company allocates a certain percentage of overhead cost to its manufactured inventory; such allocation is based on square footage and other industry-standard criteria. The Company reviews physical inventory for obsolescence and/or excess and will record a reserve if necessary. As of the date of this report, no reserve was deemed necessary.

 

Investments

 

Investments are comprised of equity holding of private companies. These investments are recorded at fair value on the Company’s consolidated balance sheet, with changes to fair value included in income. Investments are evaluated for permanent impairment and are written down if such impairments are deemed to have occurred.

 

Revenue Recognition

 

On January 1, 2018, the Company adopted the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) 606, Revenue from Contract with Customers, as amended by subsequently issued Accounting Standards Updates. This revenue standard requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to in exchange for those goods or services. The recognition of revenue is determined by performing the following consecutive steps:

 

  Identify the contract(s) with a customer;
     
  Identify the performance obligations in the contract(s);
     
  Determine the transaction price;
     
  Allocate the transaction price to the performance obligations in the contract(s); and
     
  Recognize revenue as the performance obligation is satisfied.

 

Additionally, when another party is involved in providing goods or services to the Company’s clients, a determination is made as to who—the Company or the other party—is acting in the capacity as the principal in the sale transaction, and who is merely the agent arranging for goods or services to be provided by the other party.

 

The Company is typically considered the principal if it controls the specified good or service before such good or service is transferred to its client. The Company may also be deemed to be the principal even if it engages another party (an agent) to satisfy some of the performance obligations on its behalf, provided the Company (i) takes on certain responsibilities, obligations and risks, (ii) possesses certain abilities and discretion, or (iii) other relevant indicators of the sale. If deemed an agent, the Company would not recognize revenue for the performance obligations it does not satisfy.

 

The adoption of this standard did not have a significant impact on the Company’s consolidated operating results, and accordingly no restatement has been made to prior period reported amounts.

 

The Company’s main sources of revenue are comprised of the following:

 

  Real Estate – rental income and additional rental fees from leasing of the Company’s regulatory-compliant cannabis facilities to its clients, which are cannabis-licensed operating companies. Rental income is generally a fixed amount per month that escalates over the respective lease terms, while additional rental fees are based on a percentage of tenant revenues that exceed a specified amount.
     
  Management – fees for providing the Company’s cannabis clients with corporate services and operational oversight of their cannabis cultivation, production, and dispensary operations. These fees are based on a percentage of such clients’ revenue, and are recognized after services have been performed.
     
  Supply Procurement – the Company maintains volume discounts with top national vendors of cultivation and production resources, supplies, and equipment, which the Company acquires and resells to its clients or third parties within the cannabis industry. The Company recognizes this revenue after the delivery and acceptance of goods by the purchaser.
     
 

Licensing – revenue from the sale of precision-dosed, cannabis-infused products—such as Kalm Fusion™, Nature’s Heritage™, and Betty’s Eddies™—to legal dispensaries throughout the United States. The recognition of this revenue occurs when the products are delivered.

     
  Consulting – fees from third-parties where the Company provides assistance in securing cannabis licenses, and advisory services in the areas of facility design and development, and cultivation and dispensing best practices. These fees are recognized as the services are performed.
     
  Product Sales – direct sales of cannabis, hemp, and products derived from these plants. In 2019, the Company commenced (i) the direct sale of acquired hemp seed inventory in the second quarter, and (ii) cannabis dispensary and wholesale operations of ARL in Massachusetts and the KPGs in Illinois in the fourth quarter. Future product sales are expected to include the distribution of Company-acquired and developed hemp-derived CBD product lines, and the Company’s planned cannabis-licensee acquisitions in Maryland, Nevada, and Delaware (upon this state’s amendment to permit for-profit ownership of cannabis entities). This revenue is recognized when products are delivered or at retail points-of-sale.

 

11

 

 

Research and Development Costs

 

Research and development costs are charged to operations as incurred.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation, with depreciation recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term, if applicable. When assets are retired or disposed, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income. Repairs and maintenance are charged to expense in the period incurred.

 

The estimated useful lives of property and equipment are generally as follows: buildings and building improvements, seven to thirty-nine years; tenant improvements, the remaining duration of the related lease; furniture and fixtures, seven years; machinery and equipment, five to ten years. Land is not depreciated.

 

The Company’s property and equipment are individually reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable from the undiscounted future cash flows of such asset over the anticipated holding period. An impairment loss is measured by the excess of the asset’s carrying amount over its estimated fair value.

 

Impairment analyses are based on management’s current plans, asset holding periods, and currently available market information. If these criteria change, the Company’s evaluation of impairment losses may be different and could have a material impact to the consolidated financial statements. For the six months ended June 30, 2020 and 2019, based on the results of management’s analyses, there were no impairment losses.

 

Leases

 

The consolidated financial statements reflect the Company’s adoption of ASC 842, Leases, as amended by subsequent accounting standards updates, utilizing the modified retrospective transition approach which calls for applying the new standard to all of the Company’s leases effective January 1, 2019, which is the effective date of adoption.

 

ASC 842 is intended to improve financial reporting of leasing transactions. The most prominent change from previous accounting guidance is the requirement to recognize right-of-use assets and lease liabilities on the consolidated balance sheet representing the rights and obligations created by operating leases that extend more than twelve months in which the Company is the lessee. The Company elected the package of practical expedients permitted under ASC 842. Accordingly, the Company accounted for its existing operating leases that commenced before the effective date as operating leases under the new guidance without reassessing (i) whether the contracts contain a lease, (ii) the classification of the leases, or (iii) the accounting for indirect costs as defined in ASC 842.

 

The Company determines if an arrangement is a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Non-lease components within lease agreements are accounted for separately. Right-of-use assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term, utilizing the Company’s incremental borrowing rate. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

 

Impairment of Long-Lived Assets

 

The Company evaluates the recoverability of its fixed assets and other assets in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets. Impairment of long-lived assets is recognized when the net book value of such assets exceeds their expected cash flows, in which case the assets are written down to fair value, which is determined based on discounted future cash flows or appraised values.

 

Fair Value of Financial Instruments

 

The Company follows the provisions of ASC 820, Fair Value Measurement, to measure the fair value of its financial instruments, and ASC 825, Financial Instruments, for disclosures on the fair value of its financial instruments. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value hierarchy defined by ASC 820 are:

 

Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
   
Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
   
Level 3 Pricing inputs that are generally observable inputs and not corroborated by market data.

 

12

 

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable approximate their fair values due to the short maturity of these instruments.

 

The fair value of option and warrant issuances are determined using the Black-Scholes pricing model and employing several inputs such as the expected life of instrument, the exercise price, the expected risk-free interest rate, the expected dividend yield, the value of the Company’s common stock on issuance date, and the expected volatility of such common stock. The following table summarizes the range of inputs used by the Company during the six month ended June 30, 2020 and 2019.

 

 

   Six Months Ended June 30, 
   2020   2019 
Life of instrument   3.0 years    3.0 years 
Volatility factors   1.059 to 1.180    1.059 to 1.106 
Risk-free interest rates   0.33% to 1.33%    1.76% to 2.28% 
Dividend yield   0%   0%

 

The expected life of an instrument is calculated using the simplified method pursuant to Staff Accounting Bulletin Topic 14, Share-Based Payment, which allows for using the mid-point between the vesting date and expiration date. The volatility factors are based on the historical two-year movement of the Company’s common stock prior to an instrument’s issuance date. The risk-free interest rate is based on U.S. Treasury rates with maturity periods similar to the expected instruments life on the issuance date.

 

The Company amortizes the fair value of option and warrant issuances on a straight-line basis over the requisite service period of each instrument.

 

Extinguishment of Liabilities

 

The Company accounts for extinguishment of liabilities in accordance with ASC 405-20, Extinguishments of Liabilities. When the conditions for extinguishment are met, the liabilities are written down to zero and a gain or loss is recognized.

 

Stock-Based Compensation

 

The Company accounts for stock-based compensation using the fair value method as set forth in ASC 718, Compensation—Stock Compensation, which requires a public entity to measure the cost of employee services received in exchange for an equity award based on the fair value of the award on the grant date, with limited exceptions. Such value will be incurred as compensation expense over the period an employee is required to provide service in exchange for the award, usually the vesting period. No compensation cost is recognized for equity awards for which employees do not render the requisite service.

 

13

 

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740, Income Taxes. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of operations in the period that includes the enactment date.

 

ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. The Company did not take any uncertain tax positions and had no adjustments to unrecognized income tax liabilities or benefits for the six months ended June 30, 2020 and 2019.

 

Related Party Transactions

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

In accordance with ASC 850, the Company’s financial statements include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business, as well as transactions that are eliminated in the preparation of financial statements.

 

Comprehensive Income

 

The Company reports comprehensive income and its components following guidance set forth by ASC 220, Comprehensive Income, which establishes standards for the reporting and display of comprehensive income and its components in the consolidated financial statements. There were no items of comprehensive income applicable to the Company during the period covered in the financial statements.

 

Earnings Per Share

 

Earnings per common share is computed pursuant to ASC 260, Earnings Per Share. Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing net income by the sum of the weighted average number of shares of common stock outstanding plus the weighted average number of potentially dilutive securities during the period.

 

At June 30, 2020 and 2019, there were 19,515,857 and 18,655,107, respectively, of potentially dilutive securities in the form of outstanding options and warrants. Also as of such dates, there were (i) $6.3 million and $13.75 million, respectively, of outstanding convertible debentures payable, (ii) 4,908,333 and zero shares, respectively, of Series B convertible preferred stock outstanding, and (iii) approximately $5.2 million and $350,000, respectively, of outstanding convertible promissory notes. All of these potentially dilutive securities are convertible into common stock based on either (i) a predetermined price, subject to adjustment, or (ii) the market value of common stock on or about the future conversion date.

 

For the three and six months ended June 30, 2020, all potentially dilutive securities had an anti-dilutive effect on earnings per share, and in accordance with ASC 260, were excluded from the diluted net income per share calculations, resulting in identical basic and fully diluted net income per share for these periods. Such potentially dilutive securities may dilute earnings per share in the future. For the three and six months ended June 30, 2019, the potentially dilutive securities then outstanding were convertible into 19,509,815 shares of common stock, utilizing the June 30, 2019 closing stock price of the Company’s common stock. Such share amount was included in the number of weighted average common shares outstanding on a diluted basis, and in the calculation of diluted net income per share for these periods, as shown in the statement of operations.

 

Commitments and Contingencies

 

The Company follows ASC 450, Contingencies, which requires the Company to assess the likelihood that a loss will be incurred from the occurrence or non-occurrence of one or more future events. Such assessment inherently involves an exercise of judgment. In assessing possible loss contingencies from legal proceedings or unasserted claims, the Company evaluates the perceived merits of such proceedings or claims, and of the relief sought or expected to be sought.

 

If the assessment of a contingency indicates that it is probable that a material loss will be incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

 

While not assured, management does not believe, based upon information available at this time, that a loss contingency will have material adverse effect on the Company’s financial position, results of operations or cash flows.

 

14

 

 

Beneficial Conversion Features on Convertible Debt

 

Convertible instruments that are not bifurcated as a derivative pursuant to ASC 815, Derivatives and Hedging, and not accounted for as a separate equity component under the cash conversion guidance are evaluated to determine whether their conversion prices create an embedded beneficial conversion feature at inception, or may become beneficial in the future due to potential adjustments.

 

A beneficial conversion feature is a nondetachable conversion feature that is “in-the-money” at the commitment date. The in-the-money portion, also known as the intrinsic value of the option, is recorded in equity, with an offsetting discount to the carrying amount of convertible debt to which it is attached. The discount is amortized to interest expense over the life of the debt with adjustments to amortization upon full or partial conversions of the debt.

 

Risk and Uncertainties

 

The Company is subject to risks common to companies operating within the legal and medical marijuana industries, including, but not limited to, federal laws, government regulations and jurisdictional laws.

 

Noncontrolling Interests

 

Noncontrolling interests represent third-party minority ownership of the Company’s consolidated subsidiaries. Net income attributable to noncontrolling interests is shown in the consolidated statements of operations; and the value of net assets owned by noncontrolling interests are presented as a component of equity within the balance sheets.

 

Off Balance Sheet Arrangements

 

The Company does not have any off-balance sheet arrangements.

 

Recent Accounting Pronouncements

 

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption of any such pronouncements will have a material impact on its financial condition or the results of its operations.

 

15

 

 

NOTE 3 – ACQUISITIONS

 

KPG of Anna LLC and KPG of Harrisburg LLC

 

Effective October 1, 2019, the Illinois Department of Financial and Professional Regulation approved the Company’s acquisition of (i)100% of the ownership interests of KPG of Anna LLC and KPG of Harrisburg LLC, the Company’s two cannabis-licensed clients that operate medical marijuana dispensaries in the state of Illinois (both entities collectively, the “KPGs”), and (ii) the 40% ownership interests not already owned by the Company of Mari Holdings IL LLC, the Company’s subsidiary which owns the real estate in which the KPGs’ dispensaries are located (“Mari-IL”). On such date, 1,000,000 shares of the Company’s common stock, representing the entire purchase price, were issued to the sellers of the KPGs and Mari-IL, and these entities became wholly-owned subsidiaries of the Company.

 

16

 

 

The acquisition was accounted for in accordance with ASC 805. The following table summarizes the allocation of the purchase price to the fair value of the assets acquired and liabilities assumed on the acquisition date:

 

 

Cash and cash equivalents  $443,980 
Inventory   113,825 
Intangibles   2,067,727 
Minority interests   138,356 
Accounts payable   (642,033)
Accrued expenses   (186,005)
Due to third parties   (1,020,850)
Total fair value of consideration  $915,000 

 

Based on an impairment analysis performed shortly before the filing date of this report, the Company determined the intangibles of approximately $2.1 million arising from this transaction were not impaired.

 

The Harvest Foundation LLC

 

In August 2019, the Company entered into a purchase agreement to acquire 100% of the ownership interests of The Harvest Foundation LLC (“Harvest”), the Company’s cannabis-licensed client in the state of Nevada. The acquisition is conditioned upon legislative approval of the transaction, which is expected to occur by the end of 2020. Upon consummation, the operations of Harvest will be consolidated into the Company’s financial statements.

 

The purchase price is comprised of the issuance of (i) 1,000,000 shares of the Company’s common stock, in the aggregate, to two owners of Harvest, which as a good faith deposit, were issued upon execution of the purchase agreement, (ii) $1.2 million of the Company’s common stock at closing, based on the closing price of the common stock on the day prior to legislative approval of the transaction, and (iii) warrants to purchase 400,000 shares of the Company’s common stock at an exercise price equal to the closing price of the Company’s common stock on the day prior to legislative approval of the transaction. These shares are restricted and will be returned to the Company in the event the transaction does not close by a date certain. As the transaction has not been consummated, the issued shares were recorded at par value.

 

Kind Therapeutics USA Inc.

 

In December 2018, the Company entered into a memorandum of understanding (“MOU”) to acquire Kind Therapeutics USA Inc. (“Kind”), its client in Maryland that holds licenses for the cultivation, production, and dispensing of medical cannabis. The MOU provides for a total purchase price of $6.3 million in cash, 2,500,000 shares of the Company’s common stock, and other consideration. The acquisition is subject to the approval by the Maryland Medical Cannabis Commission, which approval is not expected prior to March 2021.

 

Also in December 2018, MariMed Advisors Inc, the Company’s wholly owned subsidiary, and Kind entered into a management agreement pursuant to which the Company provides comprehensive management services in connection with the business and operations of Kind, and Mari Holdings MD LLC, the Company’s majority-owned subsidiary, entered into a 20-year lease with Kind for its utilization of the Company’s 180,000 square foot cultivation and production facility in Hagerstown, MD. Additionally, in October 2019, Mari Holdings MD LLC purchased a 9,000 square foot building in Anne Arundel County, MD for the development of a dispensary which would be leased to Kind.

 

The sellers of Kind have attempted to renegotiate the terms of the MOU. Even though the MOU contains all the definitive material terms with respect to the acquisition transaction and confirms the management and lease agreements, the selling parties now allege that the MOU is not an enforceable agreement. The Company engaged with the sellers in good faith in an attempt to reach updated terms acceptable to both parties, however the sellers failed to reciprocate in good faith, resulting in an impasse, and both parties commencing legal proceedings which are pending in the Circuit Court for Washington County, Maryland. For further information, see Note 18 – Commitments and Contingencies and Part II, Item 1. Legal Proceedings in this report.

 

17

 

 

MediTaurus LLC

 

In May 2019, the Company entered into a purchase agreement to acquire MediTaurus LLC (“MediTaurus”), a company formed and owned by Jokubas Ziburkas PhD, a neuroscientist and leading authority on CBD and its interactions with the brain and endocannabinoid system. MediTaurus currently operates in the United States and Europe and has developed proprietary CBD formulations sold under its Florance™ brand.

 

Pursuant to the purchase agreement, the Company acquired 70% of MediTaurus on June 1, 2019. The purchase price was $2.8 million, comprised of cash payments totaling $720,000 and 520,000 shares of the Company’s common stock valued at $2,080,000. The parties are currently in negotiations regarding the Company’s acquisition of the remaining 30% of MediTaurus.

 

The acquisition was accounted for in accordance with ASC 10. The following table summarizes the allocation, adjusted in September 2019, of the purchase price to the fair value of the assets acquired and liabilities assumed on the acquisition date:

 

 

Cash and cash equivalents  $64,196 
Accounts receivable   5,362 
Inventory   519,750 
Goodwill   2,662,669 
Accounts payable   (